Volume 13, Issue 1
Original Article / Published: September 2025
DOI: https://www.doi.org/10.57045/jemis/1310925.pp66-73
S. Tuncheva¹, A. Konsoulova¹, K. Kunin², P. Spasov¹, T. Karanikolova¹, M.Musin¹, I. Pandzharova¹, S. Velchova¹, Ts. Yordanov¹
1Medical Oncology Department, University Specialized Hospital for Active Treatment in Oncology„Prof. Ivan Chernozemski“, Sofia, ² Radiation Therapy Department, University Specialized Hospital for Active Treatment in Oncology„Prof. Ivan Chernozemski“, Sofia
Abstract
High-risk prostate cancer is a heterogeneous and aggressive disease, associated with increased rates of biochemical recurrence, local relapse, distant metastases, and mortality. Accumulated data from clinical trials, including the STAMPEDE study, demonstrate a significant benefit from adding Abiraterone to long- term androgen deprivation therapy (ADT) following definitive radiotherapy in patients with localized or locally advanced very high-risk prostate cancer. The combined treatment leads to a marked improvement in metastasis-free survival (MFS), progression-free survival (PFS), and overall survival (OS). Based on these results, leading international guidelines (NCCN, EAU, ESMO) now recommend Abiraterone as part of standard therapy. Despite its established role in the therapeutic algorithm, full access and reimbursement for this indication are still lacking in Bulgaria.
References
1.Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021. doi: 10.3322/caac.21660
2. Elmadani M, Mokaya PO, Omer AAA, Kiptulon EK, Klara S, Orsolya M. Cancer burden in Europe: a systematic analysis of the GLOBOCAN database (2022). BMC Cancer. 2025 Mar 12;25(1):447. doi: 10.1186/s12885-025-13862-1. PMID: 40075331; PMCID: PMC11905646.
3. Ferlay J, Colombet M, Soerjomataram I, Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.
4.Vaccarella S, Li M, Bray F, еt al. Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. BMJ 2024;386:e077738. doi: 10.1136/
bmj-2023-077738. Erratum in: BMJ 2024;386:q1995. doi: 10.1136/bmj.q1995.
5. Zumsteg ZS, Zelefsky MJ, et al. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer. BJU Int 2017;120(5B):E87-E95. doi: 10.1111/bju.13903.
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): prostate cancer version 2.2025. Plymouth Meeting, PA: NCCN; 2025. https://guidelines.nccn.org/guidelines/Prostate2_2025
7. European Association of Urology (EAU), European Association of Nuclear Medicine (EANM), European Society for Radiotherapy and Oncology (ESTRO), European Society of Urogenital Radiology (ESUR), International Society of Urological Pathology (ISUP), and the International Society of Geriatric Oncology (SIOG). 2025 EAU – EANM – ESTRO ESUR – ISUP – SIOG Guidelines on Prostate Cancer.
8. Fizazi K, Gillessen S, ESMO Guidelines committee. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents Ann Oncol2023;34(6): 557 – 563
9. James ND, Sydes MR, et al. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer–a multi-arm multi-stage randomised controlled trial. Clin Oncol (R Coll Radiol) 2008;20(8):577-81. doi: 10.1016/j.clon.2008.07.002
10. James ND, de Bono JS, Spears MR, et al; STAMPEDE Investigators. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017;377(4):338-351. doi: 10.1056/NEJMoa1702900.
11. James N, de Bono Spears MN et al.. LBA34Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT ): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). Ann Oncol2017; 28(5):620. Doi:10.1093/an- nonc/mdx440.027.
12. Attard G, Murphy L, Clarke NW, et al. Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022;399(10323):447- 460. doi: 10.1016/S0140-6736(21)02437-5.
13. Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686-700. doi: 10.1016/S1470- 2045(19)30082-8.
14. Cho E, Mostaghel EA, Russell KJ, et al. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens. IntJ Radiat Oncol Biol Phys 2015;92(2):236-43. doi: 10.1016/j. ijrobp.2015.01.020.
15. McKay RR, Xie W, Ye H, et al. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. J Urol 2021;206(1):80-87. doi: 10.1097/ JU.0000000000001702.
Keywords:
How to cite this article:
S. Tuncheva, A. Konsoulova, K. Kunin, P. Spasov, T. Karanikolova, M. Musin, I. Pandzharova, S. Velchova, Ts. Yordanov. Abiraterone in Combination with Androgen Deprivation Therapy Following Definitive Radiotherapy in Patients with Very High-Risk Prostate Cancer: A Review of Scientific Evidence and Clinical Practices. Journal of Endourology and Minimally Invasive Surgery (Bulgaria), 2025; 13(1): 66-73
Corresponding author:
Dr. Sara Tuncheva
Clinic Medical Oncology, USBAL on Oncology Prof. Ivan Chernozemski, 6 Plovdivsko Pole St. Sofia
Email: sara.tuncheva@gmail.com